FMP
Avenue Therapeutics, Inc.
ATXI
NASDAQ
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
1.88 USD
0.14 (7.45%)
About
ceo
Dr. Alexandra MacLean M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.avenuetx.comexchange
NASDAQ
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
CIK
0001644963
ISIN
US05360L3042
CUSIP
05360L205
Address
1140 Avenue of the America
Phone
781 652 4500
Country
US
Employee
3
IPO Date
Jun 27, 2017
Key Executives
